17.1 C
New Delhi

Although the pandemic is not yet over, India is unlikely to be attacked by a powerful third COVID wave: AIIMS Director Randeep Guleria

- Advertisement -

Must read

According to Director Randeep Guleria of the All India Institute of Medical Sciences (AIIMS), Delhi, a third COVID-19 wave of comparable scale to the first two is unlikely to impact India. He did warn, though, that the pandemic was far from ended, and that everyone should adhere to COVID-appropriate behaviour.

“It is improbable that a third Covid-19 wave of equal proportions to the first and second will impact India. The epidemic will eventually become endemic. We’ll keep getting cases, but the severity will be significantly reduced “Dr. Guleria explained.

The famous pulmonologist was addressing at the launch of Indian Council of Medical Research Director-General Dr Balram Bhargava’s book “Going Viral: Making of Covaxin – The Inside Story.”

Dr. Guleria also stated during the event that India does not require a booster dose at this time. According to Guleria, there is no current rise in cases, implying that immunizations are still effective against the coronavirus. He stated, “There is no need for a vaccine booster dosage or third shot for no.”

When H1N1 struck India, vaccines were brought from other countries, according to the AIIMS director. “We’ve come a long way from importing vaccines to developing our own indigenous vaccine. Our Covid vaccinations are now being sold in other countries.”

Dr. VK Paul, a member of the NITI Aayog’s Health Committee, said the choice on a third dose should be based on science. ‘Going Viral…’ attempts to take readers on a journey through the development of India’s first indigenous Covid-19 vaccine.

The book chronicles the first-hand experiences of scientists who worked nonstop for less than eight months to create India’s first indigenous Covid-19 vaccine. The novel throws light on the characters’ tenacity and bravery.

“The creation of India’s indigenous vaccine Covaxin is a true example of public-private-partnership characterised by trust and transparency,” Dr. Bhargava remarked of his book.

Prof (Dr.) Bhargava’s book also brings to light some lesser-known facts about the development of Covaxin, such as the creative manner in which scientists overcame a statewide lockdown to perform India’s first seroprevalence study.

In another tale, the author discusses how 20 monkeys helped to ensure that millions of Indians across the country had access to this life-saving vaccine.

Also read- Pankaj Tripathi to star as a lead in Srijit Mukherji’s next Sherdil

- Advertisement -

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisement -